NK News and Press, NantKwest From 02/12/21

Stocks rose this week, with investors piling into growth-oriented segments of the market. At the time of this recording, the S&P 500 (SP500) and Dow Industrials (DJI) were up 0.3% and 0.1% for the week, respectively. The Nasdaq (COMP) rallied by 0.9% while cryptocurrencies (and crypto sto...

Gainers: Artelo Biosciences (ARTL) +93%. ImmunoGen (IMGN) +29%. Prothena Corporation (PRTA) +26%. NantKwest (NK) +21%. Illumina (ILMN) +19%.Losers: Amicus Therapeutics (FOLD) -33%. CollPlant Biotechnologies (CLGN) -30%. Caladrius Biosciences (CLBS) -20%. Conformis (CFMS) -16%. SQZ Biotechnolo...

NantKwest, Inc. (NK) is up ~12.9% in the premarket after the company and its privately-held partner, ImmunityBio announced the FDA approval to expand the Phase I study of its T cell-based COVID-19 vaccine candidate.The cohort C expansion to the Phase 1 trial evaluating the subc...

Artelo Biosciences (ARTL) +63%.China Liberal Education Holdings Limited (CLEU) +59%.Helius Medical Technologies (HSDT) +29%.Denison Mines Corp. (DNN) +26% on $25M bought deal offering.Xeris Pharmaceuticals (XERS) +25% as EC OK's its Ogluo for severe hypoglycaemia.Inovio Pharmaceutic...

FDA authorized the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce comprehensive immune protection through CD4+ and CD8+ T ...

Privately-held ImmunityBio which announced to merge with NantKwest ([[NK]] -3.3%) has announced data presentation from ongoing Phase 2b study evaluating Anktiva (N-803) in non-small cell lung cancer ((NSCLC)).Clinical benefit was demonstrated in a majority of the NSCLC patients, as measured b...

Clinical benefit observed in majority of NSCLC patients who progressed on checkpoint inhibitor Anktiva ™ (also called N-803) restored or enhanced activity of checkpoint therapy even in those who progressed on the same checkpoint Activity observed regardles...

RM LAW Announces Investigation of NantKwest, Inc. PR Newswire BERWYN, Pa. , Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerning p...

The following slide deck was published by NantKwest, Inc. in conjunction with this event. For further details see: Nantkwest (NK) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

The South Africa Health Products Regulatory Authority has signed-off ImmunityBio's Phase 1 trial to evaluate its hAd5 T-cell vaccine, the company’s COVID-19 vaccine candidate.The same vaccine is currently being tested in a similar Phase 1 trial in the U.S., with no safety con...